Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mehta

Showing results (1081-1090 of 1,216) with videos related to

Pageof 122
Sort By:
Advances in Radiation Oncology|June 1, 2022
Multi-Institutional Outcomes of Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy With a Median Biologically Effective Dose of 100 Gy<sub>10</sub> for Non-bone OligometastasesTugce Kutuk, Robert Herrera, Teuta Z Mustafayev, et al.
Neuro-Oncology|June 29, 2024
The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomasConnor J Kinslow, Soumyajit Roy, Fabio M Iwamoto, et al.
Journal of Neuro-Oncology|December 4, 2009
The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guidelineMario Ammirati, Charles S Cobbs, Mark E Linskey, et al.
Journal of Neuro-Oncology|December 5, 2009
The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guidelineMinesh P Mehta, Nina A Paleologos, Tom Mikkelsen, et al.
The Lancet. Oncology|January 6, 2018
Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working groupBrian M Alexander, Paul D Brown, Manmeet S Ahluwalia, et al.
Neuro-Oncology|April 29, 2017
An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825Haley Gittleman, Daniel Lim, Michael W Kattan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trialMark R Gilbert, Meihua Wang, Kenneth D Aldape, et al.
Neuro-Oncology|October 27, 2012
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02Eudocia Q Lee, John Kuhn, Kathleen R Lamborn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2004
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium studyVinay K Puduvalli, W K Alfred Yung, Kenneth R Hess, et al.
Journal for Immunotherapy of Cancer|July 3, 2021
Systematic review of combinations of targeted or immunotherapy in advanced solid tumorsAaron C Tan, Stephen J Bagley, Patrick Y Wen, et al.
Pageof 122

Showing results (1081-1090 of 1,216) with videos related to

Sort By:
Pageof 122
Advances in Radiation Oncology|June 1, 2022
Multi-Institutional Outcomes of Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy With a Median Biologically Effective Dose of 100 Gy<sub>10</sub> for Non-bone OligometastasesTugce Kutuk, Robert Herrera, Teuta Z Mustafayev, et al.
Neuro-Oncology|June 29, 2024
The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomasConnor J Kinslow, Soumyajit Roy, Fabio M Iwamoto, et al.
Journal of Neuro-Oncology|December 4, 2009
The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guidelineMario Ammirati, Charles S Cobbs, Mark E Linskey, et al.
Journal of Neuro-Oncology|December 5, 2009
The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guidelineMinesh P Mehta, Nina A Paleologos, Tom Mikkelsen, et al.
The Lancet. Oncology|January 6, 2018
Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working groupBrian M Alexander, Paul D Brown, Manmeet S Ahluwalia, et al.
Neuro-Oncology|April 29, 2017
An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825Haley Gittleman, Daniel Lim, Michael W Kattan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trialMark R Gilbert, Meihua Wang, Kenneth D Aldape, et al.
Neuro-Oncology|October 27, 2012
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02Eudocia Q Lee, John Kuhn, Kathleen R Lamborn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2004
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium studyVinay K Puduvalli, W K Alfred Yung, Kenneth R Hess, et al.
Journal for Immunotherapy of Cancer|July 3, 2021
Systematic review of combinations of targeted or immunotherapy in advanced solid tumorsAaron C Tan, Stephen J Bagley, Patrick Y Wen, et al.
Pageof 122